

CSL Limited

ABN: 99 051 588 348 655 Elizabeth Street Melbourne Victoria 3000 Australia T +613 9389 1911 F +613 9389 1434

ASX Announcement

For immediate release 13 August 2024

APPOINTMENT OF NEW NON-EXECUTIVE DIRECTOR

Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY)

CSL Limited (ASX:CSL; USOTC:CSLLY) today announces the appointment of Ms Elaine Sorg as an independent Non-executive Director, effective 1 September 2024.

CSL's Chair, Dr Brian McNamee AO said "We are pleased to welcome Elaine to CSL's Board of Directors. She is a well-respected global leader in the biopharmaceutical industry, with a track record of successfully building franchises and brands across therapeutic areas and segments.

"Her expertise will be a strong complement to our Boards existing skillset, and be vital as CSL continues to execute on its growth ambitions."

Ms Sorg has more than 35 years' experience as a senior executive with leading pharmaceutical companies including AbbVie and Eli Lilly. Prior to her retirement in 2023, Ms Sorg was Senior Vice President for AbbVie and President of AbbVie's US commercial operations, the company's largest commercial business. She was a key leader in bringing a number of groundbreaking medicines to patients across Immunology, Oncology, Neuroscience and Eye Care.

Ms Sorg holds a Bachelor of Science (Pharmacy) from Purdue University, as well as post-graduate certifications from the University of Chicago Booth School of Management, and Harvard Business School. She is currently on the Dean's Advisory Council at Purdue University School of Pharmacy and Pharmaceutical Science, and is a Senior Advisor at the Boston Consulting Group, where she advises global health care clients on business-critical strategies and decisions.

Authorised for lodgment by:

Fiona Mead

Company Secretary

For further information, please contact:

Investors:

Chris Cooper Head, Investor Relations CSL Limited P: +61 455 022 740 Bernard Ronchi
Director, Investor Relations
CSL Limited
P: +61 3 9389 3470

Stephen McKeon
Director, Investor Relations
CSL Limited
P: 61 402 231 696

Media: Jimmy Baker Communications CSL Limited P: +61 450 909 211

E: chris.cooper@csl.com.au E: bernard.ronchi@csl.com.au E: stephen.mckeon@csl.com.au E: jimmy.baker@csl.com.au